Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

File photo of a man preparing heroin DARRYL DYCK/The Canadian Press/Press Association Images
Drugs

Two-thirds of intravenous drug users die over course of Dublin study

The results of the first longitudinal study of a community-based population of injecting drug users in Ireland showed that the majority of participants have died within the past 25 years.

TWO-THIRDS OF participants in a Trinity College Dublin study of intravenous drug users in Dublin south inner city have died since the research began 25 years ago, newly published findings show.

In 1985, some 82 intravenous heroin users agreed to take part in the study, which was the first longitudinal study of a community-based population of injecting drug users in Ireland.

By 2010, 51 of the participants had passed away. The principal cause of death (63 per cent) was a HIV-related illness.

The research, led by Dr Fergus O’Kelly, found that the average age of death for participants was 36.

The majority of the study group included single, unemployed males aged 20 to 29 years, who had served a prison sentence.

According to the study, 52 (63 per cent) of the cohort tested positive for HIV and 58 (71 per cent) for hepatitis B between 1985 and 2010. Of those living with HIV, the median survival time was 17 years  - while for those with a positive hepatitis C status, the median survival time was 21 years.

The study found that a “relatively stable” picture of HIV associated with intravenous drug users (IDUs) was now emerging in Ireland.

Researchers concluded that HIV is today a more manageable chronic disease and “poses challenges for primary care in its treatment of former and existing IDUs who are ageing and now have other chronic diseases.”

Your Voice
Readers Comments
19
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.